The inflammatory cytokines: Molecular biomarkers for major depressive disorder?

Biomarkers in Medicine

Volumn 9, Issue 2, 2015, Pages 169-180

  Martin, Charlotte ^a   Tansey, Katherine E ^a   Schalkwyk, Leonard C ^a   Powell, Timothy R ^a  

^a KING'S COLLEGE LONDON   (United Kingdom)

Author keywords

Antidepressants; Biomarkers; Cytokines; Genetic; Major depressive disorder; Proteomic; Transcriptomic

Indexed keywords

AMITRIPTYLINE; BIOLOGICAL MARKER; CYTOKINE; ESCITALOPRAM; FLUOXETINE; GAMMA INTERFERON; INTERLEUKIN 10; INTERLEUKIN 11; INTERLEUKIN 13; INTERLEUKIN 18; INTERLEUKIN 1BETA; INTERLEUKIN 4; INTERLEUKIN 6; MESSENGER RNA; MIGRATION INHIBITION FACTOR; MIRTAZAPINE; MONOAMINE OXIDASE INHIBITOR; MONOCYTE CHEMOTACTIC PROTEIN 1; NORTRIPTYLINE; PAROXETINE; PROTEIN ABCF1; REGULATOR PROTEIN; SEROTONIN UPTAKE INHIBITOR; TRICYCLIC ANTIDEPRESSANT AGENT; TUMOR NECROSIS FACTOR; UNCLASSIFIED DRUG; ANTIDEPRESSANT AGENT; AUTACOID;

GENE EXPRESSION; GENETIC ASSOCIATION; GENOTYPE; HUMAN; IMMUNE RESPONSE; INFLAMMATION; MAJOR DEPRESSION; MOLECULAR DIAGNOSIS; PATHOPHYSIOLOGY; PHARMACOGENETICS; PROTEOMICS; REVIEW; SINGLE NUCLEOTIDE POLYMORPHISM; TREATMENT RESPONSE; DEPRESSIVE DISORDER, MAJOR; DRUG EFFECTS; GENETICS; METABOLISM; TREATMENT OUTCOME;

ANTIDEPRESSIVE AGENTS; BIOMARKERS; CYTOKINES; DEPRESSIVE DISORDER, MAJOR; GENE EXPRESSION; HUMANS; INFLAMMATION MEDIATORS; POLYMORPHISM, SINGLE NUCLEOTIDE; TREATMENT OUTCOME;

EID: 84923417932     PISSN: 17520363     EISSN: 17520371     Source Type: Journal    
DOI: 10.2217/BMM.14.29     Document Type: Review

References (75)

1. Raison CL, Capuron L, Miller AH. Cytokines sing the blues: inflammation and the pathogenesis of depression. Trends Immunol. 27, 24-31 (2006).
2. Miller AH, Maletic V, Raison CL. Inflammation and its discontents: the role of cytokines in the pathophysiology of major depression. Biol. Psychiatry 65, 732-741 (2009).
3. Uher R. Genes, environment, and individual differences in responding to treatment for depression. Harv. Rev. Psychiatry 19, 109-124 (2011).
4. Baune BT, Dannlowski U, Domschke K et al. The interleukin 1 beta (IL1B) gene is associated with failure to achieve remission and impaired emotion processing in major depression. Biol. Psychiatry 67, 543-549 (2010).
5. Ustün TB, Ayuso-Mateos JL, Chatterji S, Mathers C, Murray CJL. Global burden of depressive disorders in the year 2000. Br. J. Psychiatry 184, 386-392 (2004).
6. Lanquillon S, Krieg JC, Bening-Abu-Shach U, Vedder H. Cytokine production and treatment response in major depressive disorder. Neuropsychopharmacology 22, 370-379 (2000).
7. Pandey GN, Rizavi HS, Ren X et al. Proinflammatory cytokines in the prefrontal cortex of teenage suicide victims. J. Psychiatr. Res. 46, 57-63 (2011).
8. Biomarkers Definitions Working Group. Biomarkers and surrogate endpoints: preferred definitions and conceptual framework. Clin. Pharmacol. Ther. 69, 89-95 (2001).
9. Diagnostic and Statistical Manual of Mental Disorders (Fifth Edition). American Psychiatric Association, DC, USA (2013).
10. International Classification of Diseases, 10th Revision (ICD-10). Geneva, Switerland (1992).
11. Hirschfeld RM, Lewis L, Vornik LA. Perceptions and impact of bipolar disorder: how far have we really come? Results of the national depressive and manic-depressive association 2000 survey of individuals with bipolar disorder. J. Clin. Psychiatry 64, 161-174 (2003).
12. Schmidt HD, Shelton RC, Duman RS. Functional biomarkers of depression: diagnosis, treatment, and pathophysiology. Neuropsychopharmacology 36, 2375-2394 (2011).
13. Mack CL. Serum cytokines as biomarkers of disease and clues to pathogenesis. Hepatology 46, 6-8 (2007).
14. Maes M, Bosmans E, De Jongh R, Kenis G, Vandoolaeghe E, Neels H. Increased serum IL-6 and IL-1 receptor antagonist concentrations in major depression and treatment resistant depression. Cytokine 9, 853-858 (1997).
15. Cattaneo A, Gennarelli M, Uher R et al. Candidate genes expression profile associated with antidepressants response in the GENDEP study: differentiating between baseline 'predictors' and longitudinal 'targets'. Neuropsychopharmacology 38, 377-385 (2012).
16. Powell TR, McGuffin P, Cohen-Woods et al. Putative transcriptomic biomarkers in the inflammatory cytokine pathway differentiate major depressive disorder patients from control subjects and bipolar disorder patients. PLoS ONE (2014) (In Press).
17. Powell TR, Schalkwyk LC, Heffernan AL et al. Tumor necrosis factor and its targets in the inflammatory cytokine pathway are identified as putative transcriptomic biomarkers for escitalopram response. Eur. Neuropsychopharmacol. 23, 1105-1114 (2012).
18. Uher R, Perroud N, Ng MY et al. Genome-wide pharmacogenetics of antidepressant response in the GENDEP project. Am. J. Psychiatry 167, 555-564 (2010).
19. Powell TR, Tansey KE, Breen G et al. ATP-binding cassette sub-family F member 1 (ABCF1) is identified as a putative therapeutic target of escitalopram in the inflammatory cytokine pathway. J. Psychopharmacol. 27, 609-615 (2013).
20. Ripke S, Wray NR, Lewis CM et al.; Major Depressive Disorder Working Group of the Psychiatric GWAS Consortium. A mega-analysis of genome-wide association studies for major depressive disorder. Mol. Psychiatry 18, 497-511 (2013).
21. Yu YW, Chen TJ, Hong CJ, Chen HM, Tsai SJ. Association study of the interleukin-1 beta (C-511T) genetic polymorphism with major depressive disorder, associated symptomatology, and antidepressant response. Neuropsychopharmacology 28, 1182-1185 (2003).
22. Hwang JP, Tsai SJ, Hong CJ, Yang CH, Hsu CD, Liou YJ. Interleukin-1 beta -511C/T genetic polymorphism is associated with age of onset of geriatric depression. Neuromolecular Med. 11, 322-327 (2009).
23. Borkowska P, Kucia K, Rzezniczek S et al. Interleukin-1beta promoter (-31T/C and -511C/T) polymorphisms in major recurrent depression. J. Mol. Neurosci. 44, 12-16 (2011).
24. Clerici M, Arosio B, Mundo E et al. Cytokine polymorphisms in the pathophysiology of mood disorders. CNS Spectr. 14, 419-425 (2009).
25. Haastrup E, Bukh JD, Bock C et al. Promoter variants in IL18 are associated with onset of depression in patients previously exposed to stressful-life events. J. Affect. Disord. 136, 134-138 (2012).
26. Pae CU, Yu HS, Kim TS et al. Monocyte chemoattractant protein-1 (MCP1) promoter -2518 polymorphism may confer a susceptibility to major depressive disorder in the Korean population. Psychiatry Res. 27, 279-281 (2004).
27. Jun TY, Pae CU, Chae JH. Possible association between -G308A tumour necrosis factor-alpha gene polymorphism and major depressive disorder in the Korean population. Psychiatr. Genet. 13, 179-181 (2003).
28. Cerri AP, Arosio B, Viazzoli C, Confalonieri R, Vergani C, Annoni G. The -308 (G/A) single nucleotide polymorphism in the TNF-alpha gene and the risk of major depression in the elderly. Int. J. Geriatr. Psychiatry 25, 219-223 (2010).
29. Cerri AP, Arosio B, Viazzoli C, Confalonieri R, Teruzzi F, Annoni G. -308(G/A) TNF-alpha gene polymorphism and risk of depression late in the life. Arch. Gerontol. Geriatr. 49(Suppl. 1), 29-34 (2009).
30. Bosker FJ, Hartman CA, Nolte IM et al. Poor replication of candidate genes for major depressive disorder using genome-wide association data. Mol. Psychiatry 16, 516-532 (2011).
31. Connor TJ, Leonard BE. Depression, stress and immunological activation: the role of cytokines in depressive disorders. Life Sci. 62, 583-606 (1998).
32. Levine J, Barak Y, Chengappa KN, Rapoport A, Rebey M, Barak V. Cerebrospinal cytokine levels in patients with acute depression. Neuropsychobiology 40, 171-176 (1999).
33. Thomas AJ, Davis S, Morris C, Jackson E, Harrison R, O'Brien JT. Increase in interleukin-1beta in late-life depression. Am. J. Psychiatry 162, 175-177 (2005).
34. Maes M, Song C, Yirmiya R. Targeting IL-1 in depression. Expert Opin. Ther. Targets 16, 1097-1112 (2012).
35. Bufalino C, Hepgul N, Aguglia E, Pariante CM. The role of immune genes in the association between depression and inflammation: a review of recent clinical studies. Brain Behav. Immun. 31, 31-47 (2012).
36. Hamilton JP, Etkin A, Furman DJ, Lemus MG, Johnson RF, Gotlib IH. Functional neuroimaging of major depressive disorder: a meta-analysis and new integration of base line activation and neural response data. Am. J. Psychiatry 169, 693-703 (2012).
37. El-Omar EM, Carrington M, Chow WH et al. Interleukin-1 polymorphisms associated with increased risk of gastric cancer. Nature 404, 398-402 (2000).
38. Pierson W, Liston A. A new role for interleukin-10 in immune regulation. Immunol. Cell Biol. 88, 769-770 (2010).
39. Liu J, Song B, Bai X et al. Association of genetic polymorphisms in the interleukin-10 promoter with risk of prostate cancer in Chinese. Cancer 10, 456 (2010).
40. Dinarello CA. Interleukin-18. Methods 19, 121-132 (1999).
41. Carr MW, Roth SJ, Luther E, Rose SS, Springer TA. Monocyte chemoattractant protein 1 acts as a T-lymphocyte chemoattractant. Proc. Natl Acad. Sci. USA 91, 3652-3656 (1994).
42. Mehrabian M, Sparkes RS, Mohandas T, Fogelman AM, Lusis AJ. Localization of monocyte chemotactic protein-1 gene (SCYA2) to human chromosome 17q11.2-q21.1. Genomics 9, 200-203 (1991).
43. Altamura AC, Mundo E, Cattaneo E et al. The MCP-1 gene (SCYA2) and mood disorders: preliminary results of a case-control association study. Neuroimmunomodulation 17, 126-131 (2010).
44. Locksley RM, Killeen N, Lenardo MJ. The TNF and TNF receptor superfamilies: integrating mammalian biology. Cell 104, 487-501 (2001).
45. Mossner R, Heils A, Stober G, Okladnova O, Daniels S, Lesch KP. Enhancement of serotonin transporter function by tumor necrosis factor alpha but not by interleukin-6. Neurochem. Int. 33, 251-254 (1998).
46. Zhu C, Blakely RD, Hewlett WA. The proinflammatory cytokines interleukin-1beta and tumor necrosis factor-alpha activate serotonin transporters. Neuropsychopharmacology 31, 2121-2131 (2006).
47. Tsao CW, Lin YS, Chen CC, Bai CH, Wu SR. Cytokines and serotonin transporter in patients with major depression. Prog. Neuropsychopharmacol. Biol. Psychiatry 30, 899-905 (2006).
48. Savitz J, Frank MB, Victor T et al. Inflammation and neurological disease-related genes are differentially expressed in depressed patients with mood disorders and correlate with morphometric and functional imaging abnormalities. Brain Behav. Immun. 31, 161-171 (2012).
49. Sokol CL, Barton GM, Farr AG, Medzhitov R. A mechanism for the initiation of allergen-induced T helper type 2 responses. Nat. Immunol. 9, 310-318 (2008).
50. Roger T, Chanson AL, Knaup-Reymond M, Calandra T. Macrophage migration inhibitory factor promotes innate immune responses by suppressing glucocorticoid-induced expression of mitogen-activated protein kinase phosphatase-1. Eur. J. Immunol. 35, 3405-3413 (2005).
51. Maes M, Song C, Lin A, De Jongh R, Van Gastel A, Kenis G. The effects of psychological stress on humans: increased production of pro-inflammatory cytokines and a Th1-like response in stress-induced anxiety. Cytokine 10, 313-318 (1998).
52. De Vries HE, Kuiper J, De Boer AG, Van Berkel TJC, Breimer DD. The blood brain barrier in neuroinflammatory diseases. Pharmacol. Rev. 49, 143-155 (1999).
53. Howren MB, Lamkin DM, Suls J. Associations of depression with C-reactive protein, IL-1, and IL-6: a meta-analysis. Psychosom. Med. 71, 171-186 (2009).
54. Dowlati Y, Herrmann N, Swardfager W et al. A meta-analysis of cytokines in major depression. Biol. Psychiatry 67, 446-457 (2010).
55. Alesci S, Martinez PE, Kelkar S et al. Major depression is associated with significant diurnal elevations in plasma interleukin-6 levels, a shift of its circadian rhythm, and loss of physiological complexity in its secretion: clinical implications. J. Clin. Endocrinol. Metab. 90, 2522-2530 (2005).
56. Yang K, Xie G, Zhang Z et al. Levels of serum interleukin (IL)-6, IL-1beta, tumour necrosis factor-alpha and leptin and their correlation in depression. Aust. N. Z. J. Psychiatry 41, 266-273 (2007).
57. Su S, Miller AH, Snieder H et al. Common genetic contributions to depressive symptoms and inflammatory markers in middle-aged men: the Twins Heart Study. Psychosom. Med. 71, 152-158 (2009).
58. Hiles SA, Baker AL, de Malmanche T, Attia J. A meta-analysis of differences in IL-6 and IL-10 between people with and without depression: exploring the causes of heterogeneity. Brain Behav. Immun. 26, 1180-1188 (2012).
59. Liu Y, Ho RC, Mak A. Interleukin (IL)-6, tumour necrosis factor alpha (TNF-a) and soluble interleukin-2 receptors (sIL-2R) are elevated in patients with major depressive disorder: a meta-analysis and meta-regression. J. Affect. Disord. 139, 230-239 (2012).
60. Tuglu C, Kara SH, Caliyurt O, Vardar E, Abay E. Increased serum tumor necrosis factor-alpha levels and treatment response in major depressive disorder. Psychopharmacology (Berl.) 170, 429-433 (2003).
61. Wong ML, Dong C, Maestre-Mesa J, Licinio J. Polymorphisms in inflammation-related genes are associated with susceptibility to major depression and antidepressant response. Mol. Psychiatry 13, 800-812 (2008).
62. Tadić A, Rujescu D, Müller MJ et al. Association analysis between variants of the interleukin-1b and the interleukin-1 receptor antagonist gene and antidepressant treatment response in major depression. Neuropsychiatr. Dis. Treat. 4, 269-276 (2008).
63. Barnes TC, Anderson ME, Moots RJ. The many faces of interleukin-6: the role of IL-6 in inflammation, vasculopathy, and fibrosis in systemic sclerosis. Int. J. Rheumatol. 2011, 721608 (2011).
64. Rudge JS, Eaton MJ, Mather P, Lindsay RM, Whittemore SR. CNTF induces raphe neuronal precursors to switch from a serotonergic to a cholinergic phenotype in vitro. Mol. Cell. Neurosci. 7, 204-221 (1996).
65. Thome J, Sakai N, Shin K et al. cAMP response element-mediated gene transcription is upregulated by chronic antidepressant treatment. J. Neurosci. 20, 4030-4036 (2000).
66. Cassel S, Carouge D, Gensburger C et al. Fluoxetine and cocaine induce the epigenetic factors MeCP2 and MBD1 in adult rat brain. Mol. Pharmacol. 70, 487-492 (2006).
67. Monje ML, Toda H, Palmer TD. Inflammatory blockade restores adult hippocampal neurogenesis. Science 302, 1760-1765 (2003).
68. Iosif RE, Ekdahl CT, Ahlenius H et al. Tumor necrosis factor receptor 1 is a negative regulator of progenitor proliferation in adult hippocampal neurogenesis. J. Neurosci. 26, 9793-9712 (2003).
69. Maes M. The immunoregulatory effects of antidepressants. Hum. Psychopharmacol. 16, 95-103 (2001).
70. Eller T, Vasar V, Shlik J, Maron E. Pro-inflammatory cytokines and treatment response to escitalopram in major depressive disorder. Prog. Neuropsychopharmacol. Biol. Psychiatry 32, 445-450 (2008).
71. Powell TR, Smith RG, Hackinger S et al. DNA methylation in interleukin-11 predicts clinical response to antidepressants in GENDEP. Transl. Psychiatry 3, e300 (2013).
72. Richard M, Drouin R, Beaulieu AD. ABC50, a novel human ATP-binding cassette protein found in tumor necrosis factor-alpha-stimulated synoviocytes. Genomics 53, 137-145 (1998).
73. Traks T, Koido K, Eller T et al. Polymorphisms in the interleukin-10 gene cluster are possibly involved in the increased risk for major depressive disorder. BMC Med. Genet. 9, 111 (2008).
74. Kubera M, Lin A-H, Kenis G, Bosmans E, van Bockstaele D, Maes M. Anti-inflammatory effects of antidepressants through suppression of the interferon-[gamma]/ interleukin-10 production ratio. J. Clin. Psychopharmacol. 21, 199-206 (2001).
75. Uddin M, Koenen KC, Aiello AE, Wildman DE, de los Santos R, Galea S. Epigenetic and inflammatory marker profiles associated with depression in a community-based epidemiologic sample. Psychol. Med. 41, 997-1007 (2011).